As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.
18 Analysts have issued a Gemini Therapeutics Inc forecast:
18 Analysts have issued a Gemini Therapeutics Inc forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -203 -203 |
63%
63%
|
|
| EBIT (Operating Income) EBIT | -204 -204 |
63%
63%
|
|
| Net Profit | -181 -181 |
75%
75%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Gemini Therapeutics, Inc. is a clinical-stage precision medicine company. It is developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration. The company was founded by Johanna Seddon, Paul Barlow and Andrew Herbert on March 3, 2015 and is headquartered in Cambridge, MA.
| Head office | United States |
| CEO | John Quisel |
| Employees | 125 |
| Founded | 2017 |
| Website | www.discmedicine.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


